Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2011

01-06-2011 | Original Article

Correlation of C-Reactive Protein with Clinical and Endoscopic Activity in Patients with Ulcerative Colitis

Authors: Sami Karoui, Sonia Laz, Meriem Serghini, Norsaf Bibani, Jalel Boubaker, Azza Filali

Published in: Digestive Diseases and Sciences | Issue 6/2011

Login to get access

Abstract

Background and Aims

Evaluating disease activity is important in ulcerative colitis. Laboratory markers should be a non-invasive alternative to endoscopy for patients. The objective of our study was to scrutinize the correlation between C-reactive protein (CRP) levels and clinical and endoscopic activity in ulcerative colitis patients.

Materials and Methods

We conducted a prospective study between January 2007 and December 2009. In the study we chose consecutive patients of our department with ulcerative colitis. All patients received a standardized questionnaire, clinical examination, and colonoscopy. Based on clinical and endoscopic data, we calculated the disease activity index (DAI) and the Rachmilewitz score.

Results

One-hundred and one patients were included. At the time of inclusion, 67 patients had an active disease and 34 patients were in remission. The mean DAI was 6.9 (1–12). The mean Rachmilewitz score was 4.7 (0–12). The median CRP rate was 20.2 ± 24.5 mg/l (1–107 mg/l). An increased CRP was found in 46 patients (46%). An increased CRP level was observed in patients with active disease (P < 0.0001). The DAI was higher in patients with increased CRP (9.5 ± 1.6 vs. 4.7 ± 3.6; P < 0.0001). The Rachmilewitz score was also higher in patients with increased CRP (7.2 ± 2.3 vs. 2.7 ± 3.2; P < 0.0001). A statistically significant association was found between the CRP and the DAI (r = 0.51, P < 0.0001) and between the CRP and the Rachmilewitz score (r = 0.46, P < 0.0001). The optimum cut-off of CRP level that separates active or inactive disease was calculated to be 10 ml/l, with AUC estimated at 0.81 ± 0.04 (95%CI: 0.72–0.88), a sensitivity of 67.1 (95%CI: 54.6–78.1) and a specificity of 97% (95%CI: 84.6–99.5).

Conclusion

Levels of CRP are correlated to clinical and endoscopic activity in ulcerative colitis patients.
Literature
1.
go back to reference Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn Colitis. 2008;2:1–23.CrossRef Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn Colitis. 2008;2:1–23.CrossRef
2.
go back to reference Naber AHJ, De Jong DJ. Assessment of disease activity in inflammatory bowel disease: Relevance for clinical trials. Neth J Med. 2003;61:105–110.PubMed Naber AHJ, De Jong DJ. Assessment of disease activity in inflammatory bowel disease: Relevance for clinical trials. Neth J Med. 2003;61:105–110.PubMed
3.
go back to reference Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in inflammatory bowel disease: Useful, magic or unnecessary tools? Gut. 2006;55:426–431.PubMedCrossRef Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in inflammatory bowel disease: Useful, magic or unnecessary tools? Gut. 2006;55:426–431.PubMedCrossRef
4.
go back to reference Karoui S, Serghini M, Boubaker J, Filali A. C-reactive protein: A useful tool for evaluation of clinical activity in inflammatory bowel disease? In Nagasawa S (ed) C-reactive protein: new research. Nova Science Publisher, New York. 2009:43–49. Karoui S, Serghini M, Boubaker J, Filali A. C-reactive protein: A useful tool for evaluation of clinical activity in inflammatory bowel disease? In Nagasawa S (ed) C-reactive protein: new research. Nova Science Publisher, New York. 2009:43–49.
5.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomised study. N Engl J Med. 1987;317:1625–1629.PubMedCrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomised study. N Engl J Med. 1987;317:1625–1629.PubMedCrossRef
6.
go back to reference Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J. 1989;298:82–86.CrossRef Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J. 1989;298:82–86.CrossRef
7.
go back to reference Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterlogy. Can J Gastroenterol. 2005;19:5A–36A. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterlogy. Can J Gastroenterol. 2005;19:5A–36A.
8.
go back to reference Mehdi A, Baccouche A, Skandrani K, et al. Epidémiologie des maladies inflammatoires chroniques de l’intestin dans le centre-est tunisien. Maghreb Médical. 1997;314:47–52. Mehdi A, Baccouche A, Skandrani K, et al. Epidémiologie des maladies inflammatoires chroniques de l’intestin dans le centre-est tunisien. Maghreb Médical. 1997;314:47–52.
9.
go back to reference Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices useful in assessing active intestinal inflammation in Crohn’s disease? Gut. 1989;30:1236–1240.PubMedCrossRef Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices useful in assessing active intestinal inflammation in Crohn’s disease? Gut. 1989;30:1236–1240.PubMedCrossRef
11.
go back to reference Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665.PubMedCrossRef Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665.PubMedCrossRef
12.
go back to reference Karoui S, Ouerdiane S, Serghini M, et al. Correlation between levels of C-reactive protein and clinical activity in Crohn’s disease. Dig Liver Dis. 2007;39:1006–1010.PubMedCrossRef Karoui S, Ouerdiane S, Serghini M, et al. Correlation between levels of C-reactive protein and clinical activity in Crohn’s disease. Dig Liver Dis. 2007;39:1006–1010.PubMedCrossRef
13.
go back to reference Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.PubMedCrossRef Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.PubMedCrossRef
14.
go back to reference Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851–1858.PubMedCrossRef Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851–1858.PubMedCrossRef
15.
go back to reference Osada T, Ohkusa T, Okayasu I, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol. 2008;23(2):S262–S267.PubMedCrossRef Osada T, Ohkusa T, Okayasu I, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol. 2008;23(2):S262–S267.PubMedCrossRef
16.
go back to reference Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518–1523.PubMedCrossRef Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518–1523.PubMedCrossRef
17.
go back to reference Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.PubMed Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.PubMed
Metadata
Title
Correlation of C-Reactive Protein with Clinical and Endoscopic Activity in Patients with Ulcerative Colitis
Authors
Sami Karoui
Sonia Laz
Meriem Serghini
Norsaf Bibani
Jalel Boubaker
Azza Filali
Publication date
01-06-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1496-7

Other articles of this Issue 6/2011

Digestive Diseases and Sciences 6/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine